Status:
COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how IPI-504 is abso...
Detailed Description
IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in m...
Eligibility Criteria
Inclusion
- Pathologically confirmed diagnosis of a Stage IIIb (with malignant pleural or pericardial effusion) or Stage IV NSCLC
- Measurable disease by RECIST criteria.
Exclusion
- Treatment for NSCLC with any approved or investigational product within 2 weeks of the start of IPI-504 treatment for any small molecule therapy; within 4 weeks of the start of IPI-504 treatment for any biologic or any conventional chemotherapy.
- Inadequate hematologic or renal or hepatic function
- Previous treatment with 17-AAG, DMAG or other known Hsp90 inhibitor.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00431015
Start Date
January 1 2007
End Date
December 1 2011
Last Update
December 10 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
2
Yale Comprehensive Cancer Center
New Haven, Connecticut, United States, 06519
3
Mount Sinai Comprehensive Cancer Center
Miami, Florida, United States, 33140
4
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612